Opportunity Information: Apply for RFA AI 16 047
Apply for RFA AI 16 047
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856,.
- This funding opportunity was created on May 18, 2016 and posted on May 18, 2016.
- Applicants must submit their applications by Oct 03, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) is a discretionary NIH grant opportunity (Funding Opportunity Number RFA-AI-16-047) offered through HHS/NIH under health-related funding authorities (CFDA 93.855 and 93.856). The program is aimed at supporting milestone-driven research projects led by multi-disciplinary teams that are focused on modern, structure-based vaccine design. In practical terms, the opportunity is meant to bring together expertise such as structural biology, computational modeling, protein engineering, immunology, and vaccinology to design and generate new candidate vaccine immunogens using detailed knowledge of antigen structure and immune recognition. The central goal is not simply to study pathogens in a general way, but to use structure-guided approaches to create vaccine components that are more rationally engineered to elicit protective immune responses against infectious disease pathogens that are considered clinically important.
The announcement specifically emphasizes partnerships and team science, reflecting the idea that structure-based immunogen design typically requires coordinated work across multiple specialized areas. Applicants are expected to propose projects that are driven by clear milestones, which generally means the research plan should be organized around measurable go/no-go decision points, defined deliverables, and practical progress markers that demonstrate advancement from design concepts to tangible immunogen candidates. While the provided summary does not list the exact milestones or review expectations, the milestone-driven framing signals that the funder wants projects with disciplined project management characteristics, where the work can be assessed against pre-specified technical objectives rather than only exploratory aims.
This opportunity uses the R01 funding mechanism, indicating support for a defined research project under the traditional NIH investigator-initiated grant structure, but within a targeted request for applications. The eligible applicant pool is broad and includes many types of organizations: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding universities where specified); for-profit organizations (other than small businesses); and small businesses. The listing also includes an "Others" category with direction to consult additional eligibility text, suggesting that additional entity types may qualify depending on the specific NIH eligibility language in the full announcement.
Key administrative details in the source information include the original and current closing date of October 3, 2016, with the opportunity created and posted on May 18, 2016. The announcement does not provide an award ceiling or expected number of awards in the excerpted data, so the total potential budget and the number of funded projects are not specified here. Overall, the program can be summarized as an NIH-supported, team-oriented effort to accelerate the creation of next-generation vaccine immunogens through structure-based design strategies, with an emphasis on concrete milestones and deliverable candidate immunogens targeting pathogens of significant clinical concern.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01).
What is the Funding Opportunity Number (FOA)?
The Funding Opportunity Number is RFA-AI-16-047.
Which federal agency is offering this opportunity?
This is an NIH funding opportunity offered through HHS/NIH.
What type of grant mechanism is being used?
The opportunity uses the R01 mechanism, which supports a defined research project under the traditional NIH research project grant structure, issued here as a targeted request for applications.
What is the overall purpose of the program?
The program supports milestone-driven research projects led by multi-disciplinary teams focused on modern, structure-based vaccine design. The intent is to use detailed knowledge of antigen structure and immune recognition to design and generate new candidate vaccine immunogens.
What does "structure-based design of immunogens" mean in practical terms for this FOA?
In practical terms, the work is expected to apply structure-guided approaches to create vaccine components (immunogens) that are rationally engineered, using detailed understanding of antigen structure and how the immune system recognizes it, with the aim of eliciting protective immune responses.
What kinds of expertise are expected on the project team?
The opportunity is designed to bring together multiple specialties, such as structural biology, computational modeling, protein engineering, immunology, and vaccinology.
Is this opportunity focused on basic pathogen research or on creating vaccine candidates?
The central goal is not simply to study pathogens in a general way. The emphasis is on using structure-guided methods to create tangible candidate vaccine immunogens that are engineered to elicit protective immune responses against clinically important infectious disease pathogens.
What does it mean that projects must be "milestone-driven"?
Applicants are expected to organize the research plan around measurable milestones, including go/no-go decision points, defined deliverables, and practical progress markers. The intent is that progress can be assessed against pre-specified technical objectives, not only exploratory or descriptive aims.
Does the provided summary list required milestones or specific review expectations?
No. The excerpted information emphasizes a milestone-driven framework but does not provide the exact milestone requirements or detailed review expectations.
Why does the announcement emphasize partnerships and team science?
Structure-based immunogen design typically requires coordinated work across multiple specialized areas. The FOA therefore stresses partnerships and team science to enable integrated design, engineering, and immunologic evaluation leading to candidate immunogens.
What kinds of pathogens are intended targets for this work?
The opportunity targets infectious disease pathogens that are considered clinically important. The excerpt does not list specific pathogens.
Who is eligible to apply?
The eligible applicant pool is broad and includes:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments and other tribal organizations
- Public housing authorities/Indian housing authorities
- Nonprofit organizations (501(c)(3) and non-501(c)(3), excluding universities where specified)
- For-profit organizations (other than small businesses)
- Small businesses
- Other entity types may qualify; the listing includes an "Others" category that refers applicants to additional eligibility text in the full announcement
Does the summary include an award ceiling or the expected number of awards?
No. The excerpted data does not specify an award ceiling, total potential budget, or the expected number of funded projects.
What are the CFDA numbers associated with this opportunity?
The opportunity is associated with CFDA 93.855 and CFDA 93.856.
When was the opportunity posted, and what is the closing date?
The opportunity was created and posted on May 18, 2016. The closing date listed is October 3, 2016 (noted as both the original and current closing date in the provided information).
Is this a discretionary grant opportunity?
Yes. The information describes it as a discretionary NIH grant opportunity.
What is the key outcome the funder appears to want from funded projects?
Based on the summary, the funder is aiming to accelerate the creation of next-generation vaccine immunogens using structure-based design strategies, with progress demonstrated through clear milestones and deliverable candidate immunogens.
Browse more opportunities from the same category: Health
Next opportunity: Long-term Exposure to Air Pollution and Development of Cardiovascular Disease
Previous opportunity: Enabling Technologies for Advanced Combustion Systems
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 16 047
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 16 047) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
| Developing New Clinical Decision Support to Disseminate and Implement Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 282 Funding Number: PA 16 282 Agency: HHS-AHRQ Category: Health Funding Amount: $750,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Specialized Center Cooperative Agreements (U54) Apply for RFA OD 16 011 Funding Number: RFA OD 16 011 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Comprehensive Platform for Integrated Communication Initiative (CPICI) Apply for RFA 621 16 000003 Funding Number: RFA 621 16 000003 Agency: USAID-TAN Category: Health Funding Amount: $46,200,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Resource Cooperative Agreement (U42) Apply for RFA OD 16 012 Funding Number: RFA OD 16 012 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Scaling Established Clinical Decision Support to Facilitate the Dissemination and Implementation of Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 283 Funding Number: PA 16 283 Agency: HHS-AHRQ Category: Health Funding Amount: $500,000 |
| Establishment of Centers of Excellence in Refugee Health Apply for CDC RFA CK12 120505CONT16 Funding Number: CDC RFA CK12 120505CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Addressing Ebola and other Highly Infectious Diseases Internationally Apply for CDC RFA CK15 15050203SUPP16 Funding Number: CDC RFA CK15 15050203SUPP16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Systems Approach to Immunity and Inflammation (U19) Apply for RFA AI 16 050 Funding Number: RFA AI 16 050 Agency: HHS-NIH11 Category: Health Funding Amount: $1,500,000 |
| Limited Interaction Targeted Epidemiology (LITE) to Advance HIV Prevention (UG3/UH3) Apply for RFA AI 16 031 Funding Number: RFA AI 16 031 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| HIV/AIDS Vaccine Facility (C06) Apply for PAR 16 290 Funding Number: PAR 16 290 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R01) Apply for PA 16 295 Funding Number: PA 16 295 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 047", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.